Stocky turns companies like Mineralys Therapeutics, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Stocky rates Mineralys Therapeutics, Inc. at 30/100 based on business quality, leadership alignment, valuation.
Every stock is scored across six dimensions built to answer one question — can this business keep compounding? — without a Bloomberg subscription. Here's the actual snapshot for Mineralys Therapeutics, Inc.:
Quality + moat + leadership + valuation fused into a single 0–100 number. When you see 30/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
We don't claim a backtest. The top-scoring basket is recorded every month and measured against the S&P 500 from that date onward — judged on what it said before the outcome was known. The record is young, and published as it stands.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Mineralys Therapeutics, Inc. (MLYS) at 30/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation into a single number.
MLYS's current Stocky Verdict is 30/100, placing it in the "Avoid" band. This composite combines a 26/100 Compounder score, Leadership, 10/100 Moat rating.
Mineralys Therapeutics, Inc. rates Limited moat (10/100 Moat Score) — based on 10-year return-on-invested-capital, pricing power, switching costs and network effects. Wide moats compound; Limited moats erode.
Leadership Alignment for Mineralys Therapeutics, Inc. is under analysis. Stocky scores founder tenure, insider ownership, CEO compensation multiple-of-salary, and long-term shareholder value creation.
Mineralys Therapeutics, Inc.'s Resilience Profile scores 75/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Mineralys Therapeutics, Inc..
Sign up free and unlock the full analysis on MLYS — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for MLYS in the app.
